{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:28:26Z","timestamp":1790155706769,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Grant-in-Aid for Scientific Research","award":["15K09600"],"award-info":[{"award-number":["15K09600"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.clim.2017.01.014","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T00:30:17Z","timestamp":1486081817000},"page":"56-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Anti-BlyS antibody reduces the immune reaction against enzyme and enhances the efficacy of enzyme replacement therapy in Fabry disease model mice"],"prefix":"10.1016","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8042-0069","authenticated-orcid":false,"given":"Yohei","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toya","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2017.01.014_bb0005","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nbt.1484","article-title":"Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment","volume":"26","author":"Wang","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.clim.2017.01.014_bb0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.clim.2017.01.014_bb0015","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.clim.2017.01.014_bb0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2007.06.013","article-title":"Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy","volume":"92","author":"Ohashi","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.clim.2017.01.014_bb0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymgme.2008.03.008","article-title":"Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease","volume":"94","author":"Ohashi","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.clim.2017.01.014_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2017.01.014_bb0035","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-014-0169-6","article-title":"Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study","volume":"9","author":"Schiffmann","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.clim.2017.01.014_bb0040","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-mediated inhibition of enzyme replacement therapy in Fabry disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.clim.2017.01.014_bb0045","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2249.2004.02567.x","article-title":"Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease","volume":"137","author":"Garman","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2017.01.014_bb0050","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genitourin. Med."},{"key":"10.1016\/j.clim.2017.01.014_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067052","article-title":"Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT","volume":"8","author":"Banugaria","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2017.01.014_bb0060","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/eci.12.40","article-title":"Immune modulation in Pompe disease treated with enzyme replacement therapy","volume":"8","author":"Banugaria","year":"2012","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.clim.2017.01.014_bb0065","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1177\/0883073813485819","article-title":"Immune tolerance induced using plasma exchange and rituximab in an infantile Pompe disease patient","volume":"29","author":"Deodato","year":"2014","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.clim.2017.01.014_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2013.03.002","article-title":"B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease","volume":"163","author":"Elder","year":"2013","journal-title":"J. Pediatr."},{"key":"10.1016\/j.clim.2017.01.014_bb0075","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/pbi.12413","article-title":"Oral delivery of acid alpha glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice","volume":"13","author":"Su","year":"2015","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.clim.2017.01.014_bb0080","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar2506","article-title":"Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus","volume":"10","author":"Furie","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2017.01.014_bb0085","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/art.24699","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus","volume":"61","author":"Wallace","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2017.01.014_bb0090","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.clim.2015.03.022","article-title":"BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease","volume":"158","author":"Doerfler","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2017.01.014_bb0095","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jgm.1566","article-title":"Minimum requirement of donor cells to reduce the glycolipid storage following bone marrow transplantation in a murine model of Fabry disease","volume":"13","author":"Yokoi","year":"2011","journal-title":"J. Gene Med."},{"key":"10.1016\/j.clim.2017.01.014_bb0100","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ymgme.2005.01.007","article-title":"Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry","volume":"85","author":"Kitagawa","year":"2005","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.clim.2017.01.014_bb0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood.V90.1.43","article-title":"Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase","volume":"90","author":"Ponce","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clim.2017.01.014_bb0110","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ymgme.2013.08.002","article-title":"The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5years and older treated with intravenous idursulfase","volume":"110","author":"Barbier","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.clim.2017.01.014_bb0115","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.clim.2017.01.014_bb0120","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2249.2008.03602.x","article-title":"Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model","volume":"152","author":"Joseph","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2017.01.014_bb0125","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.4049\/jimmunol.1303326","article-title":"Transient low-dose methotrexate generates B regulatory cells that mediate antigen-specific tolerance to alglucosidase alfa","volume":"193","author":"Joly","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.01.014_bb0130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/gim.2012.110","article-title":"Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease","volume":"15","author":"Banugaria","year":"2013","journal-title":"Genitourin. Med."},{"key":"10.1016\/j.clim.2017.01.014_bb0135","first-page":"30","article-title":"Immune tolerance strategies in siblings with infantile Pompe disease-advantages for a preemptive approach to high-sustained antibody titers","volume":"4","author":"Stenger","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.clim.2017.01.014_bb0140","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/mt.2012.133","article-title":"Administration of anti-CD3 antibodies modulates the immune response to an infusion of alpha-glucosidase in mice","volume":"20","author":"Ohashi","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.clim.2017.01.014_bb0145","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1093\/hmg\/ddt052","article-title":"TFEB regulates lysosomal proteostasis","volume":"22","author":"Song","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.clim.2017.01.014_bb0150","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"Tondel","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.clim.2017.01.014_bb0155","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"Alpha-galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661617300864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661617300864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T16:50:05Z","timestamp":1601571005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661617300864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":31,"alternative-id":["S1521661617300864"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2017.01.014","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-BlyS antibody reduces the immune reaction against enzyme and enhances the efficacy of enzyme replacement therapy in Fabry disease model mice","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2017.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}